丙型肝炎疫苗研究的新理念、挑战与策略

贾战生; 马力; 韦三华; 姚志强

丙型肝炎疫苗研究的新理念、挑战与策略

1. 第四军医大学唐都医院全军感染病诊疗中心
2. 第四军医大学唐都医院临床实验与检验输血科
3. Department of Internal Medicine,Division of Infectious Diseases,James H.Quillen College of Medicine,East Tennessee State University,Johnson City,TN

基金项目:

国家863专项课题(2007AA02Z441)； “十一五”重大传染病防治专项课题(2009ZX10004-715)；

详细信息

中图分类号: R392
计量
- 文章访问数: 4058
- HTML全文浏览量: 21
- PDF下载量: 1118
- 被引次数: 0
出版历程
- 出版日期: 2011-01-20

New ideas, challenges and strategies about research on hepatitis C vaccine

Research funding:

摘要

摘要:
丙型肝炎病毒（HCV）感染是引起慢性肝病的主要原因之一,严重危害人类健康,目前抗病毒治疗的标准方案为聚乙二醇干扰素α（PEG-IFN-α）联合利巴韦林,其有效率仅为50%70%,且疫苗研究进展缓慢,已成为严峻的公共卫生问题。近10多年来,对HCV感染发病机制、保护性免疫应答和病毒持续感染机制的认识取得了很大进展,中和抗体以及CD4+和CD8+T细胞在内的强烈的T细胞免疫应答已被证明与HCV的清除相关,这将是研制丙型肝炎疫苗的希望所在。当前HCV疫苗的研究主要集中在多肽疫苗、核酸疫苗、病毒载体疫苗、重组多表位疫苗、以抗原递呈细胞为载体的树突状细胞（DC）疫苗等,已有多种疫苗正在研制并进行进入临床试验前的测试。我们结合多年来对HCV的研究基础,通过与国内外同行交流,提出变"单纯预防"为"防治结合,以诱导持续免疫应答和维持病毒抑制状态为基本目标"的HCV疫苗研究新理念,发展以诱导细胞免疫为主的预防和治疗性疫苗,尤其是既能在体内有效激发HCV特异性细胞毒性T淋巴细胞（CTL）反应,又能维持CD4+记忆T细胞功能的治疗性细胞疫苗。本文综述关于HCV保护性免疫应答及持续感染的...
- 肝炎,丙型 /
- 病毒性肝炎疫苗
Abstract:
Hepatitis C virus (HCV) is a major public health problem and a leading cause of chronic liver disease.Unfortunately, there is no vaccine against HCV and the current standard anti-viral therapy is the combination of pegylated IFN-α with ribavirin, which is only effective in 50%-70% of the patients with HCV infection.Great strides have been made over the past decades, and much has been learned about the pathogenesis of hepatitis C, protective immunity against HCV and causes of persistent infection.Neutralizing antibodies and robust T cell responses including both CD4+ and CD8+ have been shown to be related to the clearance of HCV, which have shed lights on the potential success of HCV vaccines.Recently, there are many HCV vaccines under development, including multi-peptides vaccines, DNA vaccines, recombinant multi-epitopes vaccines, dendritic cell vaccines, etc and many of which were tested before entering into clinical trials.After years of HCV research, it is suggested that we should change our ideas in HCV vaccine research from simply prevention to the cooperation of prevention and treatment, which could induce the persistent immune response and virus inhibition.In this review, we discuss the protective host immunity against HCV and the mechanisms of persistent HCV infection, the challenges, new ideas and strategies in HCV vaccine research are also included.
- hepatitis C /
- viral hepatitis vaccines

HTML全文

参考文献(43)

[1]Shepared CW, Finelli L, Alter MJ.Global epidemiology of hepatitis C virus infection[J].Lancent Infect Dis, 2005, 5:558-567.

[2]Zeuzem S, Poordad F.Pegylated-interferon plus ribavirin therapy in the treatment of CHC:individualization of treatment duration according to on-treatment virologic response[J].Curr Med Res Opin, 2010, 26 (7) :1733-1743.

[3]Yu CI, Chiang BL.A new insight into hepatitis C vaccine development[J].J Biomed Biotechnol, 2010, 2010:548280.Epub 2010 Jun 13.

[4]Stoll-Keller F, Barth H, Fafi-Kremer S, et al.Development of hepatitis C virus vaccines:challenges and progress[J].Expert Rev Vaccines, 2009, 8 (3) :333-345.

[5]Law M, Maruyama T, Lewis J, et al.Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge[J].Nature Medicine, 2008, 14 (1) :25-27.

[6]Forns X, Payette PJ, Ma X, et al.Vaccination of ch-impanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV[J].Hepatology, 2000, 32 (3) :618-625.

[7]Dahari H, Feinstone SM, Major ME.Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins[J].Gastroenterology, 2010, 139 (3) :965-974.

[8]Frey SE, Houghton M, Coates S, et al.Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults[J].Vaccine, 2010, 28 (38) :6367-6373.

[9]Bowen DG, Walker CM.Adaptive immune responses in acute and chronic hepatitis C virus infection[J].Nature, 2005, 436 (7053) :946-952.

[10]Thimme R, Bukh J, Spangenberg HC, et al.Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease[J].Proc Natl Acad Sci U S A, 2002, 99 (24) :15661-15668.

[11]Dazert E, Neumann-Haefelin C, Bressanelli S, et al.Loss of viral fitness and cross-recognition by CD8+T cells limit HCV escape from a protective HLA-B27-restricted human immune response[J].J Clin Investi, 2009, 119 (2) :376-386.

[12]Smyk-Pearson S, Tester IA, Klarquist J, et al.Spontaneous recovery in acute human hepatitis C virus infection:functional T-cell thresholds and relative importance of CD4 help[J].J Virol, 2008, 8 (24) :1827-1837.

[13] Semmo N, Day CL, Ward SM, et al.Preferential loss of IL-2-secreting CD4+T helper cells in chronic HCV infection[J].Hepatology, 2005, 41 (5) :1019-1028.

[14]Shoukry NH, Cawthon AG, Walker CM.Cell-mediated immunity and the outcome of hepatitis C virus infection[J].Annu Revi Microbiol, 2004, 58:391-424.

[15]Urbani S, Amadei B, Fisicaro P, et al.Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviralmemory CD8 responses[J].Hepatology, 2006, 44 (1) :126-139.

[16]Stamataki Z, Grove J, Balfe P, et al.Hepatitis C virus entry and neutralization[J].Clin Liver Dis, 2008, 12 (3) :693-712.

[17]Bustin LB, Rice CM.Flying under the radar:the im-munobiology of hepatitis C[J].Annu Rev Immunol, 2007, 25:71-99.

[18]Limmer A, Ohl J, Kurts C, et al.Efficient presentation of exogenous antigen by liver endothelial cells to CD8+T cells results in antigen-specific T-cell Tolerance[J].Nat Med, 2000, 6:1348-1354.

[19]Racanelli V, Rehermann B.The liver as an immunological organ[J].Hepatology, 2006, 43 (2 Suppl 1) :s54-62.

[20]GM Lauer, E Barnes, M Lucas, et al.High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection[J].Gastroenterology, 2004, 127 (3) :924-936.

[21]Firbas C, Boehm T, Buerger V, et al.Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine[J].Vaccine, 2010, 28 (12) :2397-2407.

[22]Yutani S, Komatsu N, Shichijo S, et al.Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-J Clini Hepatol, January 2011, Vol.27, No.1class I-A alleles[J].Cancer Science, 2009, 100 (10) :1935-1942.

[23]Yutani S, Yamada A, Yoshida K, et al.Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy[J].Vaccine, 2007, 25 (42) :7429-7435.

[24]Yu H, Huang H, Xiang J, et al.Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3[J].J Gen Virol, 2006, (87) :1-10.

[25]Gao M, Wang HP, Wang YN, et al.HCV-NS3 Th1 minigene vaccine based on invariant chain CLIP genetic substitution enhances CD4 (+) Th1 cell responses in vivo[J].Vaccine, 2006, 24 (26) :5491-5497.

[26]BacardíD, Amador-Ca-izares Y, Cosme K.Toxicology and biodistribution study of CIGB-230, a DNA vaccine against hepatitis C virus[J].Hum Exp Toxicol, 2009, 28 (8) :479-491.

[27]冯志华, 周永兴, 焦成松, 等.Th1类细胞因子对pHCV-C重组体诱生免疫应答的增强作用[J].中国病毒学杂志, 2001, 16 (2) :101-104.

[28]Fournillier A, Gerossier E, Evlashev A, et al.An ac-celerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses[J].Vaccine, 2007, 25 (42) :7339-7353.

[29]Habersetzer F, Zarski JP, Leroy V, et al.A novel vectori-zed HCV therapeutic vaccine (TG4040) :results of a phase I study in naive patients chronically infected by HCV in Proceedings of the 44th Annual Meeting of the European Association for the Study of the Liver (EASL'09) [R].Copenhagen, Denmark, April 2009.

[30]Larsson M.The dendritic cell:the immune system's adjuvant--a strategy to develop a HCV vaccine?[J].Gastroenterology, 2006, 130 (2) :603-606.

[31]Koido S, Tanaka Y, Tajiri H, et al.Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells[J].Vaccine, 2007, 25 (14) :2610-2619.

[32]Anderson MJ, Shafer-Weaver K, Greenberg NM, et al.Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer[J].J Immunol, 2007, 178 (3) :1268-1276.

[33]Vietheer PT, Boo I, Drummer HE, et al.Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies[J].Antivir Ther, 2007, 12 (4) :477-487.

[34]Cheong WS, Drummer HE, Netter HJ.Delivery of a foreign epitope by sharing amino acid residues with the carrier matrix[J].J Virol Methods, 2009, 158 (1-2) :35-40.

[35]Wei SH, Yin W, An QX, et al.A novel HCV vaccine approach using recombinant BCG expressing multi-epitope antigen[J].Archieve of viology, 2008, 153 (6) :1021-1029.

[36]郝春秋, 冯志华, 贾战生, 等.复制缺陷型HCV C基因腺病毒表达载体的构建包装及鉴定[J].世界华人消化杂志, 2003, 11 (2) :144-147.

[37] 周云, 李端, 陈琳, 等.HCV多CTL表位树突状细胞疫苗的构建及体外刺激T细胞反应[J].临床肝胆病杂志, 2011, 27 (1) :40-44.

[38]Li W, Li J, Tyrrell DL, et al.Expression of hepatitis C virus-derived core or NS3 antigens in human dendritic cells leads to induction of pro-inflammatory cytokines and normal T-cell stimulation capabilities[J].J Gen Virol, 2006, 87 (Pt 1) :61-72.

[39]Firbas C, Jilma B, Tauber E, et al.Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine:a randomized, placebo controlled trial for dose optimization in 128 healthy subjects[J].Vaccine, 2006, 24 (20) :4343-4353.

[40]Vider-Shalit T, Raffaeli S, Louzoun Y.Virus-epitope vaccine design:informatic matching the HLA-I polymorphism to the virus genome[J].Mol Immunol, 2007, 44 (6) :1253-1261.

[41]Day CL, Lauer GM, Robbins GK, et al.Broad specificity of virus specific CD4+T helper cell responses in resolved hepatitis C virus infection[J].J Virol, 2002, 76 (24) :12584-12595.

[42]韦三华, 尹文, 雷迎峰, 等.HCV多表位基因重组BCG的筛选及其诱导的免疫应答研究[J].中华微生物学和免疫学杂志, 2007, 27 (11) :1041-1045.

[43]Li D, Xie YW, Jia ZS.Forecasting of hepatitis C virus CTL epitopes and design of multi-epitopes vaccine[J].Zhonghua Gan Zang Bing Za Zhi, 2009, 17 (10) :786-787.

施引文献

资源附件(0)

访问统计